Browsing Tag
REZOLVE-AD
3 posts
Nektar Therapeutics (NASDAQ: NKTR) raises $460m as rezpegaldesleukin data strengthens Phase 3 autoimmune outlook
Nektar Therapeutics raised $460 million after strong rezpegaldesleukin data. Find out what this means for Phase 3 trials and autoimmune drug markets.
Nektar Therapeutics (NASDAQ: NKTR) rezpegaldesleukin shows dual action in skin and asthma — is this a pipeline turning point?
Nektar Therapeutics’ rezpegaldesleukin delivers dual efficacy in dermatitis and asthma in Phase 2b REZOLVE-AD trial. See how this Treg-based therapy is changing the game.
Breakthrough REZOLVE-AD results position Rezpegaldesleukin as a potential first-in-class IL-2 Treg therapy for atopic dermatitis and asthma
Rezpegaldesleukin delivers strong dual skin and asthma results in the REZOLVE-AD study — find out how Nektar Therapeutics plans to advance its IL-2 Treg platform in 2026.